Highland Capital Management (Tennessee)’s Bristol-Myers Squibb BMY Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,672	Closed	-$1.98M	–	419
2026 Q1	$1.98M	Buy	+32,672	New	+$1.9M	0.1%	169
2024 Q3	–	Sell	-66,145	Closed	-$2.75M	–	377
2024 Q2	$2.75M	Sell	66,145 -5,544	-8%	-$248K	0.16%	146
2024 Q1	$3.89M	Sell	71,689 -742	-1%	-$37.8K	0.22%	124
2023 Q4	$3.72M	Buy	72,431 +225	+0.3%	+$11.8K	0.23%	130
2023 Q3	$4.19M	Sell	72,206 -5,625	-7%	-$345K	0.29%	101
2023 Q2	$4.98M	Sell	77,831 -1,155	-1%	-$77.5K	0.32%	96
2023 Q1	$5.47M	Sell	78,986 -520	-0.7%	-$36.7K	0.41%	69
2022 Q4	$5.72M	Sell	79,506 -400	-0.5%	-$30.2K	0.4%	63
2022 Q3	$5.68M	Sell	79,906 -3,650	-4%	-$265K	0.44%	57
2022 Q2	$6.43M	Buy	83,556 +3,120	+4%	+$238K	0.46%	50
2022 Q1	$5.87M	Buy	80,436 +1,810	+2%	+$122K	0.35%	77
2021 Q4	$4.9M	Sell	78,626 -1,100	-1%	-$64.5K	0.28%	104
2021 Q3	$4.72M	Sell	79,726 -3,110	-4%	-$205K	0.29%	102
2021 Q2	$5.54M	Sell	82,836 -42,480	-34%	-$2.77M	0.33%	81
2021 Q1	$7.91M	Buy	125,316 +31,844	+34%	+$1.98M	0.49%	59
2020 Q4	$5.8M	Sell	93,472 -36,099	-28%	-$2.22M	0.37%	73
2020 Q3	$7.81M	Sell	129,571 -1,636	-1%	-$98.5K	0.56%	49
2020 Q2	$7.71M	Buy	131,207 +9,825	+8%	+$588K	0.6%	44
2020 Q1	$6.77M	Sell	121,382 -17,824	-13%	-$1.09M	0.64%	42
2019 Q4	$8.94M	Buy	139,206 +34,624	+33%	+$1.98M	0.62%	47
2019 Q3	$5.3M	Buy	+104,582	New	+$4.92M	0.39%	76
2018 Q4	–	Sell	-22,964	Closed	-$1.43M	–	310
2018 Q3	$1.43M	Buy	22,964 +11,042	+93%	+$655K	0.1%	188
2018 Q2	$660K	Sell	11,922 -150	-1%	-$8.1K	0.05%	255
2018 Q1	$764K	Buy	12,072 +1,610	+15%	+$104K	0.06%	239
2017 Q4	$641K	Buy	10,462 +366	+4%	+$22.9K	0.05%	244
2017 Q3	$644K	Buy	10,096 +2,267	+29%	+$132K	0.05%	239
2017 Q2	$436K	Sell	7,829 -11,027	-58%	-$600K	0.04%	284
2017 Q1	$1.02M	Sell	18,856 -3,650	-16%	-$200K	0.08%	189
2016 Q4	$1.32M	Sell	22,506 -6,560	-23%	-$359K	0.11%	176
2016 Q3	$1.57M	Buy	29,066 +21,356	+277%	+$1.37M	0.13%	168
2016 Q2	$567K	Sell	7,710 -10	-0.1%	-$707	0.05%	252
2016 Q1	$493K	Buy	+7,720	New	+$487K	0.04%	258
2015 Q4	–	Sell	-750	Closed	-$44K	–	335
2015 Q3	$44K	Hold	750	–	–	﹤0.01%	387
2015 Q2	$50K	Buy	+750	New	+$49.4K	﹤0.01%	384

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Highland Capital Management (Tennessee)'s BMY Position: Q2 2026 in Review

Highland Capital Management (Tennessee) sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 32,672 shares — an estimated $1.98M sold.

Highland Capital Management (Tennessee) first reported a position in BMY in Q2 2015 and held it in 34 quarters. The position peaked at $8.94M in Q4 2019. 1,238 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Highland Capital Management (Tennessee) reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 32,672 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.98M.
Highland Capital Management (Tennessee) first reported a position in Bristol-Myers Squibb in Q2 2015 and held it in 34 quarters.
Highland Capital Management (Tennessee)'s Bristol-Myers Squibb position peaked at $8.94M in Q4 2019.
1,238 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.